Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH)

• Fugl Meyer Motor Scale score [ Time Frame: Baseline and 90 days ] [ Designated as safety issue: No ]
  Change from Baseline in Fugl Meyer Motor Scale score at 90 days
  
  

• Barthel Index [ Time Frame: Baseline and 90 days ] [ Designated as safety issue: No ]
  Change from Baseline in Barthel Index at 90 days
  
  
• modified Rankin Scale [ Time Frame: Baseline and 90 days ] [ Designated as safety issue: No ]
  Change from Baseline in modified Rankin Scale at 90 days
  
  
• NIH Stroke Scale [ Time Frame: Baseline and 90 days ] [ Designated as safety issue: No ]
  Change from Baseline in NIH Stroke Scale at 90 days
  
  

Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a great amount of disability, economic and social burden. This is particularly true in developing countries where it accounts for between 20% and 50% of all strokes. Pharmacological and surgical interventions have been attempted to diminish the mortality and disability derived from ICH, with unsuccessful results. Recently the use of Fluoxetine in addition to physical rehabilitation has been proven useful to improve motor recovery from cerebral infarct. The purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral hemorrhage.

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial. This trial will recruit 86 patients with intracerebral hemorrhage of both sexes, ages >18 years, from four Mexican hospitals. The patients will receive either 20mg of fluoxetine or a placebo once daily for 90 days. The primary outcome is the mean change in Fugl-Meyer Motor Scale score between inclusion (day 0) and day 90. The secondary outcomes will be changes in Barthel Index, Modified Rankin scale and National Institutes of Health (NIH) Stroke Scale. The outcomes will be measured at day 45±7days and at day 90, for a total of four visits with each subject (at screening and at 0, 45 and 90days).